Kazazian Asset Management LLC boosted its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 62.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,283 shares of the biopharmaceutical company’s stock after purchasing an additional 6,669 shares during the period. Alexion Pharmaceuticals accounts for approximately 2.1% of Kazazian Asset Management LLC’s portfolio, making the stock its 13th biggest position. Kazazian Asset Management LLC’s holdings in Alexion Pharmaceuticals were worth $2,067,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Factory Mutual Insurance Co. increased its stake in Alexion Pharmaceuticals by 104.5% during the fourth quarter. Factory Mutual Insurance Co. now owns 358,500 shares of the biopharmaceutical company’s stock valued at $42,873,000 after acquiring an additional 183,200 shares during the period. Creative Planning grew its stake in shares of Alexion Pharmaceuticals by 72.2% in the 4th quarter. Creative Planning now owns 27,773 shares of the biopharmaceutical company’s stock valued at $3,321,000 after purchasing an additional 11,642 shares during the period. Chicago Equity Partners LLC bought a new stake in shares of Alexion Pharmaceuticals in the 3rd quarter valued at approximately $320,000. Johnson Financial Group Inc. grew its stake in shares of Alexion Pharmaceuticals by 13,840.0% in the 3rd quarter. Johnson Financial Group Inc. now owns 4,182 shares of the biopharmaceutical company’s stock valued at $587,000 after purchasing an additional 4,152 shares during the period. Finally, Boston Advisors LLC grew its stake in shares of Alexion Pharmaceuticals by 3.0% in the 4th quarter. Boston Advisors LLC now owns 149,241 shares of the biopharmaceutical company’s stock valued at $17,848,000 after purchasing an additional 4,315 shares during the period. 95.36% of the stock is owned by institutional investors and hedge funds.
ALXN has been the topic of several recent analyst reports. BidaskClub raised Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, December 27th. Zacks Investment Research downgraded Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th. Morgan Stanley upped their price objective on Alexion Pharmaceuticals from $148.00 to $151.00 and gave the stock an “overweight” rating in a report on Friday, February 9th. Credit Suisse Group reaffirmed a “buy” rating and set a $166.00 price objective on shares of Alexion Pharmaceuticals in a report on Tuesday, December 12th. Finally, Raymond James Financial reissued an “outperform” rating and issued a $130.00 price target (down previously from $178.00) on shares of Alexion Pharmaceuticals in a research note on Thursday, January 4th. They noted that the move was a valuation call. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and twenty have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $155.55.
Shares of NASDAQ ALXN traded down $0.07 during mid-day trading on Friday, hitting $109.24. The company had a trading volume of 2,380,843 shares, compared to its average volume of 2,530,641. Alexion Pharmaceuticals, Inc. has a one year low of $96.18 and a one year high of $149.34. The stock has a market capitalization of $24,305.99, a price-to-earnings ratio of 21.17, a PEG ratio of 1.01 and a beta of 1.13. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.10 and a quick ratio of 2.62.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.09 by $0.39. The business had revenue of $909.70 million during the quarter, compared to the consensus estimate of $880.38 million. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. Alexion Pharmaceuticals’s revenue was up 9.5% on a year-over-year basis. During the same period last year, the business posted $1.26 EPS. sell-side analysts expect that Alexion Pharmaceuticals, Inc. will post 6.12 EPS for the current year.
In related news, EVP John B. Moriarty sold 1,261 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $117.26, for a total value of $147,864.86. Following the transaction, the executive vice president now directly owns 20,210 shares of the company’s stock, valued at $2,369,824.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Heidi L. Wagner sold 655 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $117.26, for a total transaction of $76,805.30. Following the completion of the transaction, the senior vice president now directly owns 32,635 shares in the company, valued at $3,826,780.10. The disclosure for this sale can be found here. Insiders have sold 28,700 shares of company stock valued at $3,345,708 over the last 90 days. Company insiders own 4.35% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Kazazian Asset Management LLC Acquires 6,669 Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/07/kazazian-asset-management-llc-purchases-6669-shares-of-alexion-pharmaceuticals-inc-alxn.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.